» Articles » PMID: 33507915

Personalized Logical Models to Investigate Cancer Response to BRAF Treatments in Melanomas and Colorectal Cancers

Overview
Specialty Biology
Date 2021 Jan 28
PMID 33507915
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The study of response to cancer treatments has benefited greatly from the contribution of different omics data but their interpretation is sometimes difficult. Some mathematical models based on prior biological knowledge of signaling pathways facilitate this interpretation but often require fitting of their parameters using perturbation data. We propose a more qualitative mechanistic approach, based on logical formalism and on the sole mapping and interpretation of omics data, and able to recover differences in sensitivity to gene inhibition without model training. This approach is showcased by the study of BRAF inhibition in patients with melanomas and colorectal cancers who experience significant differences in sensitivity despite similar omics profiles. We first gather information from literature and build a logical model summarizing the regulatory network of the mitogen-activated protein kinase (MAPK) pathway surrounding BRAF, with factors involved in the BRAF inhibition resistance mechanisms. The relevance of this model is verified by automatically assessing that it qualitatively reproduces response or resistance behaviors identified in the literature. Data from over 100 melanoma and colorectal cancer cell lines are then used to validate the model's ability to explain differences in sensitivity. This generic model is transformed into personalized cell line-specific logical models by integrating the omics information of the cell lines as constraints of the model. The use of mutations alone allows personalized models to correlate significantly with experimental sensitivities to BRAF inhibition, both from drug and CRISPR targeting, and even better with the joint use of mutations and RNA, supporting multi-omics mechanistic models. A comparison of these untrained models with learning approaches highlights similarities in interpretation and complementarity depending on the size of the datasets. This parsimonious pipeline, which can easily be extended to other biological questions, makes it possible to explore the mechanistic causes of the response to treatment, on an individualized basis.

Citing Articles

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway.

Huang Z, Lou K, Qi M, Wang J, Li L, Sun B J Transl Med. 2024; 22(1):1052.

PMID: 39574120 PMC: 11583401. DOI: 10.1186/s12967-024-05828-x.


Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression.

Hemedan A, Satagopam V, Schneider R, Ostaszewski M iScience. 2024; 27(10):110956.

PMID: 39429779 PMC: 11489052. DOI: 10.1016/j.isci.2024.110956.


Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy.

Taoma K, Ruengjitchatchawalya M, Liangruksa M, Laomettachit T PLoS One. 2024; 19(2):e0298788.

PMID: 38394152 PMC: 10889607. DOI: 10.1371/journal.pone.0298788.


PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks.

Ponce-de-Leon M, Montagud A, Noel V, Meert A, Pradas G, Barillot E NPJ Syst Biol Appl. 2023; 9(1):54.

PMID: 37903760 PMC: 10616087. DOI: 10.1038/s41540-023-00314-4.


Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers.

Ivanisevic T, Sewduth R Proteomes. 2023; 11(4).

PMID: 37873876 PMC: 10594525. DOI: 10.3390/proteomes11040034.


References
1.
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

2.
Fey D, Halasz M, Dreidax D, Kennedy S, Hastings J, Rauch N . Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal. 2015; 8(408):ra130. DOI: 10.1126/scisignal.aab0990. View

3.
Cantwell-Dorris E, OLeary J, Sheils O . BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10(3):385-94. DOI: 10.1158/1535-7163.MCT-10-0799. View

4.
Hyman D, Puzanov I, Subbiah V, Faris J, Chau I, Blay J . Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015; 373(8):726-36. PMC: 4971773. DOI: 10.1056/NEJMoa1502309. View

5.
Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P . Molecular targeted therapy of -mutant colorectal cancer. Ther Adv Med Oncol. 2019; 11:1758835919856494. PMC: 6582307. DOI: 10.1177/1758835919856494. View